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To compare the benefit of angiolensin-converting enzyme inhibi .
don and direct vasodilation an The prognosis of advanced heart
failure, 117 patients evaluated for cardiac Iransplaniation also
had sever, symptoms and abnormal hemmtynmsdc status at rest
were randomized to treatment with either captopril or hydrala-
zlne plus isosorbide dindrate (Ha-C Trial) . Comparable hemody-
namic
effects of the two regimens were ought by litratiug
vasodilator doses to match the hemodynamic slaws achieved with
nitreprosside and diuretic agents, attempting to achieve a puhm-
rary capillary wedge pressure of 15 mm Big and a systemic
vascular resistance of 1,240 dynes .s. em-s. Treatment with the
alternate vasodilator was started because of poor he.nodynamie
respumve or side effects (40% of patients in the captoprll group and
22% In the hydralazine group) . .Adequetr hemodynamit response
in patients with a serum sodium level <135 ntgfdl was more likely
with hydrnlazine than with captaprit (71% vs, 33%, p = 0-d4),
Ioorblde dfultrate was prescribed t 88% of
the
hydralaaine-
treated patients and Sdvro of the captopril-treated patients . The
hemudynamie improvements from each regimen were rqulvalent .
Heart failure is characterized hemodynamically by elevated
left ventricular filling pressure and increased systemic vas-
cular resistance That can adversely affect left ventricular
performance
. By antagonizing systemic vasoconstriction
and altering the funding conditions on the left ventricle,
vasodilaturs improve the hemodynamic and etirriccl status in
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After 8 ± 7 months of follow-up, the actuarial 1-year survival
rate was 81% in the caplopril-tr^ated patients and 51% in the
hydralazine .treated patients 1p = 7.05). The improved survival
with eaplopril resulted from a lower rate of sudden death, which
occurred in only 3 of 44 eaplopril-treated patients compared with
17 1 60 hydralazine-treated patients (p = 0.61). In the subset of
patients who continued treatment with the initial vasodilator,
results were similar to those for the entire treatment group . Cox
multivariate analysis revealed that therapy with capmpril, low
pulmonary capillary wedge pressure during therapy and serum
sodium were each an independent predictor of survival .
This study demonstrates that angidmsiaconverdng enzyme
Inhibition with capleprll confers an additional benefit over that
achieved by direct vasodilation with, hydralazine when doses are
titrated to achieve the same
hemmdyaamic goals and nitrates are
included in both regimeua . This dimr6al
affect
am mortality
results primarily from a decrease in sudden death,
(J Am
loll Cordial 1992;19:847SO)
patients with heart failure (1-4) . Both direct vasodilation
with a combination of hydralazine and isosorhide dinitrate
(5) and angiotensin-converting wzyate inhibition with enal-
opril 161, have reduced the atonality rate from that achieved
with placebo when these agents arc added empirically to
therapy in patients receiving digitalis and diuretic drugs . In
previous studies, vasodilator doses were increased to an
arbitrary maximal dose unless hypotension or other side
effects developed.
In patients with advanced heart failure . vasodilators in
conjunction with diuretics can be tailored to approach the
hemodynamic goals of near normal ventricular filling pres-
sures and systemic vascular resistance. with a concomitant
decrease in venuicafar volumes, reduction in atrioven-
tricular (AV) valve regurgitation and increase in cardiac
output
. When tailored to these goals, both the hydralazine-
isosorbide dinitrate combination and angiocensin-converting
enzyme inhibition have allowed stabilization without surgery
0735.105715255 .00
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for many patients rcfcnxd to urgent cardiac hansplanlatiun
after failure of empiric doses of vasodilators 171 .
Direct vasodilation has not been compared with angioten-
sin-converting edzyme inhibition in a randomized prespec-
dve study of patients with advanced heart failure and heme-
dynamic compromise at rest . If vasodilators mediate their
beneficial effect on mortality solely through their hemody-
namic effects, equivalent hemodynamic achievement with
either regimen should yield an equivalent reduction in men-
tality. However, if neurohumoral inhibition is important
independent of its hemodynamic effects, a difference in
mortality reduction between the regimens wuuld be ex-
pected even if equivalent hemodynamic eficcts were
achieved. This trial was designed to study the effect en
mortality of direct vasodilation with hydralazine and isosor.
bide dinitrate compared with angiotensin
.converting enzyme
inhibition with captopril when the agents were titrated to the
same hemodynamic goals in patients with advanced heart
failure .
Methods
Study patients. This was a prospective randomized trial
in patients with severe heart failure associated with marked
left ventricular dilation and impaired systolic function (mean
left ventricular ejection fraction 20%) . The patients were
referred to evaluation for nrthotopic hear transplantation
and all had congestive heart failure symptoms at rest or on
minimal exertion (New York Heart Association functional
class III or IV) despite therapy with digitalis, diuretic drugs
and empiric doses of vasodilators
. Coronary arleriography
was performed if it had not been performed earlier ; coronary
artery disease was considered significant if there was >705b
diameter narrowing in a major artery- Left ventricular ejec-
tion fraction was measured by radionuclide angiography or
two-dimensional echocardiography . Patients were excluded
for the following reasons myocardial infarction within the
previous 2 months, unstable angina, right heart failuredue to
pulmonary disease, restrictive cardiomyopathy, serum cce-
atinine w2.5 mg/dl or a primary noncardiac medical condi-
tionthat in itself was believed to limit the likelihood oft-year
survival
. The study group comprised 117 consecutive eligi-
ble patients who underwent the standard procedure of
evaluation and met the hemodynamic criteria of the study
protocol. Consent was obtained before right heart catheter-
ization and the protocol was approved by the Human Sub-
ject Protection Committee on September 22, 1988 .
Hemodynamte protocol.
At the time of referral, patients
were receiving treatment with digitalis, diuretics and empiric
doses of vasodilators . Vasodilators were discontinued for I
to 2 days when possible and all patients underwent right
heart catheterization as part of the evaluation for transplan-
tation
. The pulmonary artery flotation catheter was left in
place in patients with a pulmonary capillary wedge pressure
>20 mm Hg or cardiac index =_22liters'min per m 2 , or both.
Hemodynamic measurements were repeated hourly for 2 to
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4 h without a change in medication . The-dilution cardiac
output determination was performed with iced solution in
triplicate or until three readings agreed within 10%
.
If hemodynamic variables remained outside these criteria
at 210 4 h, patients were randomized to treatment with either
captopril or the combination of hydralazine and isosorhide
dinitrate. Therapy was then initiated with nitroprusside
infusion and intravenous €urosemide thirsted to approach the
he mod y namic goals ofa pulmurar, capillary wedge pressure
w15 mm He and systemic vascular resistance <1,2110
d, ers ram
while systolic blood pressure was maintained
at =_80 mm Hg as previously described t6,41 . After these
goals were reached or 49 h elapsed, patients were started on
treatment with the previously selected oral vasodilator
. As
the nitroprnsside therapy was gradually withdrawn . the oral
vasodilator dose was adjusted to maintain the optimal hemo-
dynamic status that had been achieved with nitroprusside .
Administration of .aplepril was started at an initial dose of
6 .25 mg titrated up to a maximum of 100 mg every 6 h as
needed. Administration of hydrlazine was started at an
initial dose of 25 mg titrated up to 150 ring every 6 h as
needed
. Isosorhide dinitrate was given to all patients ran-
domized to hydralazine therapy but was discontinued if
intolerable side effects occurred. Isosorbide dinitrate was
added to the captopril regime i if the patient had a history of
coronary artery disease or if the pulmonary capillary wedge
pressure remained >20 mm Hg after 24 h of captopril
titration . The initial isosorhide dinitrate dose of 10 mg was
titrated up to 80 mg every b h as needed .
Although the hemodynamic goals described earlier were
sought, values for systemic vascular resistance <I,300
dynes-s'cm - ', pulmonary capillary wedge pressure
<20 tam rig and right atria] pressure <10 mm Hg with
systolic blood pressure >80 mm Hg wove considered accept-
able . If acceptable hemodynamic status could not be
achieved or serious side effects developed, the initial vaso-
dilator was discontinued and patients were begun on treat-
ment with the alternate vasodilamr after optimal hemody-
namic status was again obtained with nitraprusside . If
acceptable hemodynamic status was still not achieved, the
oral vasoditater that resulted in valises that most closely
approximated the desired status was given . Final hemody-
namic measurements were obtained during oral easodiator
therapy, after at least four dosing intervals before catheter
removal . Patients were discharged on treatment with the oral
vasodilator, digoxin and a iiexible regimen of loop diuretics
with intermittent metolozdne to maintain weight within 2 In
(0 .9 kg) of discharge weight.
Antlarrhythmic therapy. When the study began, admin-
istration of type I antiarrhythmic agents was initiated or
continued in patients with atrial fibrillation . symptomatic
ventricular taehyeardia or a history of sudden death . Once
the results of the Cardiac Arrhythmia Suppression Trial
(CAST) (l0) became available in August 1';89, all newly
enrolled patients (n = 64) underwent 24-h Holier monitoring
and those found to have high grade asymptomatic ventricu-
844
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Jar arrhylhmias were started on a low dose amiodamne
protocol with 200 sa day after h modified loading schedule .
Eicctrophysiologic testing was performed for evaluation of
syncope or known ventricular tachycardia in nine patients,
The mointcnance dose of amiodaronc for patients with
inducible ventricular tachycardia was 400 mgiday .
Foltass.up . After discharge . patients were seen weekly
until criteria for clinical stability were met([[) and every 2 to
12 weeks as needed (hereafter . Vasodilator dose and other
medications were adjusted as clinically indicated fur deteri-
orating renal function or symptomatic hypolension, which
occurred only rarely during follow-up. Cardiac lransplanta-
tinn was recommended In patients who worm jedgcd by the
transplant team lobe eligible because of irreversible disease .
recent history of severe symptoms. poor exercise capacity,
high risk of sudden death and absence of major noncardiac
illness as previol€sly uullined
(12).
The principal end praise of the trial nws IHarnliry, The
trial also analyzed readmission for orgenl transplantation as
an end point
. Causes of death were defined in accordance
with a modified version of the American Heart Association's
recommendations
(13) . with sudden death defined as death
occurring out of the hospital- during sleep or w i thin 15 min of
the onset of symptoms. Death duringa hospital stay required
for worsening symptoms of congestive heart failure was
considered a heart failure death. To compare mortality once
hemodynamic stabilization had been achieved on the two
oral vasodilator regimens, the study wa' designed to include
only those patients discharged from the initial hospital stay
without transplantation .
Statistical analysis
. Survival cloves were calculated with
the product-limit fKaplan-Mcicrl estimate using the BMDP
etatisticot package (141,
with transplant candidates being
withdrawn at the time of transplantation . The four patients
without apparent hemodynamic deterioration whose dis-
charge vasodilator regimen was discontinued or who had an
additional vasodilator introduced by an outside physician
were withdrawn at that time
.
For clarity of interpretation, survival differences are
presented as absolute differences, rather than as a percent of
percentages
. Survival curves were compared with the Man-
tel-Cox statistic- Univariate aralysis was performed with use
of the baseline variables of age- presence oferaro nary artery
disease, ejection fraction . atria] fibrillation, serum sodium,
serum creatinine and blood urea nitrogen and the treatment
variables of the antiarrhythmic agent, aspirin, coumadin and
dtgoxin
. Hemodynamic variables of heart rate, blood pres-
sure. right atrial
. pulmonary artery systolic and pulmonary
capillary wedge pressures
. cardiac index and systemic vas-
cular resistance were included both at baseline and after the
tailoring of therapy with oral vasodilators
. Variables signif-
icant with a p value of 0 .1t' in univarinte analysis were
rntcr:d
:rte ah- Cax proportional hazards etude!, which
retained all indepeneent varisthis with a p value of 0,10
(l4) .
Frequencies of adequate response and other drug therapy in
vasodilator study groups were compared with the chi-square
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Table I . Clinical Characteristics 01104 Polienls With Heart
Failure in the Two Treatment Groups
Sons sodium Intg/dll 136 a 5 135 x 6
serum orealinine onprdh 1
.3 a 0 .3
1
.3 x 0.3
= NS fr all benches animal charenerisllcs .
00101 ambulatory
electrs ardioeraphk monitoring obtained in 27 061r) of 44
oplopril-Imated
patients and 37 (62%) of N) hydralazine-treated patients al baseline study.
I N = left ventricular : LVEDD = teri vcnlrialar end .dieslohc dimension
:
NSVT = nonsrsminaa venrrknlar tachycardia ore 24-h Halter monitoring:
NYHA = New York Hei m Association
: PVC1 = premature ventricular
mmpleses per hour em 24-h Holier monitoring .
or Fisher exact test . All anhtvses were performed in both the
entire patient group recording to the vabudilatur regimen
prescribed at discharge and in the subset of patients dis .
charged on the same regimen to which they were random-
ized . The subset
of patients discharged on the initial random-
ized regimen was also compared with
the subset of patients
discharged on the alternate regimen after withdrawal from
the initial regimen,
Results
Patient randomisation, Patients were randomly assigned
to treatment between September 1908 and July 1990, with
follow-upending November 1950, is total of 117 patients met
hemodynnmic criteria and were enrolled in the study ; 59
patients were randomized to captopril and 35 patients to
hydralazine and is-bide dinitrata therapy . Of the 117
patients, 63 (S4%n) had coronary artery disease and 54 (46p/)
had heart failure unrelated to eesronary artery disease
. All
patients were in New York Heart Association functional
class Ill or IV . Of the 117 patients, the condition of 13 could
not be stabilized for discharge on an oral vasodilator regi-
men; 6 of the 13 required heart transplantation during the
first hospital stay (4 randomized to hydralazine and 2 to
captopril therapy)
. 3 died during the first hospital stay (I
Treatment Group
Coplonril
(11 = 44.
Hydruttaine
,n - 60)
Age yet 53 It 51 ! 15
Mile )41 91 a2
Eluoey Cri
Ischemic 68 52
Idioearhia 25 40
Alcoholic 5
Vuloelar 5 a
NYHA class tt
II l 22 20
v rs se
rjseson macron 0.21 •_ 0 .1 0.19 m o.6
l.VFDEI -l 75- 10 77--9
4VIttom_bos (PPl 11 S
Atria) Shrillnrnn
I'al 23 20
7-1 ;., -. hi 41h 1
23 12
PVC1hIn=64H
195±355 190±251
N5VTIn=641101'
20 62
IACC Vol . 19, No, 4
M-1, 15. 1992 :941-50
Table 2 . Hemodynamic Response to "therapy in 104 Patient,
Tremmenr Group
Capmpdl
	
Hvdrnlaeme
to ..44)' In=em'
'All variables except heart rare changed sgnihcamly between baseline
and after therapy (pc0 .04l, -0.05hCoWenvasodilatorTreatment group, .
MAP - mean medal pressure ; PEW - pulmonary capillary wedge pre-re:
RA = right aerial pressure
. SVR = systemic vaxular ri sislarae
.
randomized to hydralazine and 2 to captopril therapy) . 2
were transferred for terminal care (both randomized to
hydralazine therapy) and 2 required a combination of by-
dralazine or minoxidil with captopril for stabilization for
discharge (both randomized to hydralazine therapy) . Be-
cause the purpose of the study was to compare mortality
rates with the two oral vasodilator regimens after initial
hemodynamic stabilization had been achieved, these 13
patients were excluded from the subsequent analysis .
Results of randomized therapy . Among the remaining 104
patients, the initial randomly selected dilator failed to
achieve optimal hemodynamic status or caused side effects
in 22 (4 0% ) of the 55 patients initially receiving captopril and
It (22%) of the 49 patients initially receiving hydralazine
(p = NS between groans)
; administration of the initial agent
was then discontinued and treatment with the alternate agent
begun . The reasons for discontinuing captopril were persist .
ent high systemic vascular resistance (n
-
12), symptomatic
hypotension with systolic blood pressure :80 mm Hg (n =
8), deteriorating renal function In = I) and persistent hyper-
kalemia (n = I). The reasons for discontinuing hydralazine
were high pulmonary capillary wedge pressure (n = 3) . high
systemic vascular resistance (n
- 2), 4/ aziness In = 2), rash
(n = 2), hepatitis (n = I) and nausea (n = 1) . The hemody.
namic goals were less likely to be achieved with captopril in
patients with hyponatremia than in patients with normal
serum sodium levels. Among patients with serum sodium
e 135 mg/dl, the hentodynantic goals were achieved and the
original randomized regimen continued in only 6 (33%) of 18
receiving captopril compared with 12 (71%) of 17 receiving
hydralazine (p - 0.04)
.
Final treatment groups (Tables I to 3). The final treatment
groups thus consisted of the 44 patients discharged on
treatment with captoprit (as the initial vasodilator in 33 and
the alternate in 11 ; average dose 206 1 147 mg/day) and 60
patients discharged on treatment with hydralazine (as the
initial vasodilator in 38 and the alternate in 22 : average dose
p - Ns for rrequefs3
of dwg lhempy .
410 - 164 mglday)
. These two groups of patients had similar
clinical and hemodynamic profiles at baseline study (Tables
I and 2). Ail patients treated with hydralazine were initially
started on treatment with isosorhide dinitrate, with occa-
sional discontinuation for side effects . whereas the caplopri!-
treated patients were started on treatment with nitrates as
indicated for coronary artery disease or required for addi-
tional preload reduction, resulting in discharge on isosorhide
dinilrate therapy (Table 3) for 84% of the captopril group
(average dose 94 ± 83 mg/day) and 88% of the hydralazine
group (average dose 114 ± 93 mg/dayl
.
Final measurements demonstrated marked improvement
in hemodynamic variables in both treatment groups (Table
2)
. Identical values for average right atria) pressure, sys-
temic vascular resistance and pulmonary capillary wedge
pressure were achieved .  Although the increase in heap rate
in the hydralazine group and the decrease in the captopril
group were not significant, the final heart rate was slightly
higher (94 vs. 88 beats/min, p - 0.05) in the hydralazine-
treated patients, yielding a higher cardiac output (4 .9 vs. 4 .4
liters/min . p -
0 .01) with no significant difference in stroke
volume (53 vs . 51 and, p - NS) . Afterevatuation and therapy .
62 of the 104 patients discharged were on the waiting list for
heart transplantation with regular outpatient priority . The
vasodilator regimen prescribed at discharge on the basis of
hcr„odynamic response was well tolerated, with only eight
patients (8%) requiring adjustments in dosing (two receiving
hydralazine and six receiving captoprit) and four patients
(4r%l requiring discontinuation or a change in vasodilator
because of
side effects once they were discharged home
(three on hydralazine and one on capteprit therapyl . No
patient was lost to fallow-up . Readmission for ergcnt heart
transplantation
was required in only 5 patients (2 on hydrala-
zine and 3 on captopril therapy) : 17 patients underwent
standard priority heart transplantation as stable outpaten!s
after an average wait of 6 months (8 on hydralazine and 9 on
captopril therapy) .
Survival. After a mean follow-up interval of 8 1 7
months . the actuarial survival rate was 81% at 6 months and
81% at I year in the captopril-treated patients and 67% at 6
FONA6(69%ETAt_
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Ircmmcm t '-p
Cupippnl
m
14)
Itydrul oinc
a = em
uiv(91,. 41 Ma, 3,,ssr,
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Type l u ;,at, SOP", 16127'8
Amioduronc
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figure 1. KsplamMeier survival curves far the 104 patients dis-
charged an the oral vasodilmor regimen of captopril (Cpt) (n = 44)
or hydralazine (Hyd) (n = 60) plus isosorbide dinitrate .
months and 51% at I year in the hydralazine-treated patients
(p = 0 .05) (Fig . 1) . Including the five readmissions for urgent
transplantation as end points yielded a similar difference .
Univariate analysis of age, left ventricular ejection fraction,
presence of coronary artery disease, atria) fibrillation, serum
sodium, serum creatinine, initial and final hemodynanic
measurements and type of vasodilator, antiarrhythmic
agent, coumadin, aspirin and digoxin treatment showed the
only predictors of mortality to be elevated final pulmonary
capillary wedge pressure (p = 0.001), low serum sodium (p =
0 .004) and hydralazine treatment (p = 0 .04) . Multivariate
analysis showed these three variables to be independent
predictors of overall mortality
: elevated final pulmonary
capillary wedge pressure (p - 0 .001), low serum sodium (p -
0 .02) and hydralazine treatment (p = 0.05) . The benefit of
captopril treatment was most apparent in patients with
pulmonary capillary wedge pressure >16 mm Hgon therapy,
whose 1-year survival rate was 82% with captopril versus
18% with hydralazine (p = 0 .01) . The survival difference was
nut significant in patients achieving a lower pulmonary
capillary wedge pressure on therapy .
Mode of death (Table 4). Sudden cardiac death accounted
for 20 (56%) of the 36 deaths, occurring in 3 of 44 captopril-
treated patients and 17 of 60 hydralazine-treated patients .
Table 4 . Cause of Death in 104 Patients
'p < 0.05
.
Treatment Group
Captopnl Hydralazne
In = 441 (n = 60)
Cardiac death
Sudden death 3 (7%)' 17 )28%P
Heart failure death 5 (11%) 8 113%)
Other cardiovascular death I I
Nencardievascular death
0
Total mortality
10(23%)• 26(43%1-
TALC Vol . 19. No. 4
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Figure 2. Knplan-Meier curves of sudden death in the 104 patients
discharged on (he oral vasodilator regimen or captopril (Cpt) (n
44) or hydralazine (Hyd) (n = 60) plus isosorbide dinitmte .
Multivariate analysis using sudden death as the end point
revealed that treatment with hydralazine compared with
captopril predicted sudden death (p = 0 .007) independent of
the only other predictor, high final pulmonary capillary
wedge pressure (p = 0 .04). Although serum sodium was an
independent predictor of overall mortality, it was not pre-
dictive of sudden death in this severely compromised group
of patients . The actuarial incidence of sudden death at I year
was 5% in the captopril-treated patients and 37% in the
hydralazine-treated patients (p - 0 .01) (Fig. 2) . There were
too few deaths due to progressive heart failure to determine
if vasodilmortherapy was predictive of this end point (5 of 44
captopril-treated patients and 8 of 60 hydralazine-treated
patients, p - NS) and on multivariate analysis the only
predictor of progressive heart failure death was serum so-
dium (p = 0
.014). There were three deaths due to other
causes (ecrehrovascular accident, gastrointestinal bleeding
and ruptured aortic aneurysm)
.
Analysis of subgruups . For overall survival, the benefit of
captopril was seen in hyponatremic patients with serum
sodium %135 mg/dl (I-year survival rate 76% in the captopril
group vs. 28% in the hydralazine group, p = 0.05) and was
not significant in patients with serum sodium >135 mg/dl
(84% vs
. 71%, p = 0.27) . For prevention of sudden death,
captopril treatmem conferred significant benefit in both
normonatremic (3% vs. 23% at I year, p - 0 .05) and
hyponatremic (7% vs . 56%, p = 0.05) patients . The sudden
death rate was lower in patients treated with captopril who
had coronary artery disease (7% vs . 44% at 1 year, p = 0.03)
as well as in those patients without coronary artery disease
(0% vs. 33%, p = 0 .05). The sudden death rate was also
lower in patients treated with captopril who had nonsus-
tained ventricular tachycardia on Holler ambulatory electro-
cardiographic monitoring as well as in those patients without
nonsustained ventricular tachycardia .
Analysis of the subset of 71 patients who continued
treatment with the initial randomized vasodilator revealed
on .-
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Fig.. S Kaplan-Maize r vat curvev in the euhgenr of '.1
patients who remained an the initial randomized vasodilator regimen
of captopril (Cptl In = 33) or hydralazinc IHyd) In = 381 plus
isovatbide dinilrate. Survival differences are similar to those in the
larger heterogeneous group shown in Figure I .
results that were similar to those obtained for the entire
treatment group of 104 patients. Baseline hemodynamic
measurements and clinical characteristics were similar in the
two groups and there were comparable hemodynamic im-
provements with therapy
. The I-year actuarial survival rate
was 86% for captopril-treated patients and 53% for tsydrata-
ziua-treoled patients (p = 0 .05) (Fig, 3) . The I-year incidence
of sudden death was 3% in the captopril-treated patients and
33% in the hydralazine-Ireated patients (p = 0.041 . in mul-
tivmate analysis of this subset, vasodil!ntor treatment with
hydralazinc remained predictive of overall meuloltty JP
0.041 and sudden death (p = 0.03).
The 22 patients originally randomized to captopril but
discharged on hydralazinc therapy were computed with the
38 patients originally randomized to hydraiazirr and also
discharged on hydratazine therapy. The I-year actuarial
survival rate for these two groups was 48% versus 53500 (p =
NS) . The incidence of sadden death was 7 or 22 versus 10 of
38 (p = NSI
.
Discussion
This trial demonstrated that the mortality rate of patients
with advanced heart failure was lower at I year in those
treated with captopril than in those treated with hydralazine
(19% vs, 49%) even though the drug doses were titrated to
achieve the same hemodynamic goals. The lower mortality
associated with captopril was independent of the hemody-
namic status achieved during dose tit ration and was predonF
inaptly due to a reduction in sudden death .
Vasodilator trials and survival. Vasodilators have been
employed in the management of heart failure ID reduce
ventricular outflow resistance, filling pressures and AV
valve regurgitation with reuniting hemodynamic and clinical
improvement (8,15-17) . In the Veterans Administration
rov -m ---
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Heart Failure Trial 1 (5) . the combination of hydralazinc and
ismorblde dinitrale reduced the 2 year mortality rate to 26f/,
from 34'7 with placebo. in patients with mild to moderate
heart failure . demonstrating that the hemodynamic improve-
mom achieved with direct vasodilators could Improve sue-
steal .
In advanced heart failure, a
tivatiort of the neuroendo-
crine systems also contributes to ventricular dysfuneteen,
decempensalien and death. In the Cooperative North Scan-
dinacian Enalapril Survival Study 161, treatment with enala-
pri1- which inhibits the renin-angiotensin system, reduced
the mortality rate from 52% with placebo to 36% at the end
of I year in policnts whose heart failure was less severe than
that in our study group . In a retrospective nnnmndomizcd
analysis of 203 patients with severe heart failure
. Lee and
Nacker 113) reported that angiotensin-converting enzyme
inhibition with caplopril or enalapril appcarca to result in
increased survival in hyponatremic patients . whereas direct
vasodilation with hydralazinc, isosorbide dinitrate and alpha-
adrenergic blockade with prezosin did not . The randomized
Veterans Administration Heart Failure Trial 11 (19) com-
pared empiric doses of enalapril with hydralazine and iso-
sorbide dinitrale in patients with mild to moderate heart
failure and showed a modest reduction in the mortality rate
with enalapril from 25% to 18% at 2 years . In these previous
studies- vasodilator doses were increased to arbitrary max-
imal doses unless limited by hyputension or other side
effects . Thus . it has not been established whether the benefit
of angiotensinconverting enzyme inhibition extends beyond
its hemodynamic impact, which should be of most relevance
in the patients with hemodynamic compromise at rest caused
by advanced heart failure .
Hemodynamies and survival. In patients with advanced
heart failure who are severely limited despite previous
empiric treatment with vasodilators, intensive therapy wit`
either captopril, often with the addition of isosorhide dini .
Irme . or the combination of hydralazinc and isosorbide
dinilrate, in doses titrated to allempl to achieve normal
ventricular filling pressures and systemic vascular resis-
tance, can frequently improve clinical status and reduce the
incidence of rehospitaiianion
(7) .
The hemodynamic re-
sponse of loading conditions jeut not of cardiac output)
during the titration of therapy predicts clinical stability after
discharge fill and the I-year survival rate (20). Because
hemodynamic profiles are important in these patients, it is
necessary to achieve equivalent hemodynamic impact to
determine whether neurohumoral inhibition provides an
additional independent benefit over that of direct vasodila-
tion in advanced heart failure. By titrating both vasodilator
regimens to the same hemodynamic goals, this trial was
designed not only to ecmpare direct vasodilatidn and an-
giolensin-converting enzyme inhibition, but also to deter-
mine whether the effect an mortality was independent of
early hemodynamic effects.
This study showed that with captopril the mortality rate
a! I year was reduced to 19% from 49% with hydralazine
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when both regimens included nitrates . On average . caplopril
treatment did result in a lower cardiac output, heart rate and
mean arterial pressure. but these are nor the hemodynamic
variables previously shown to correlate with survival in
advanced hears failure. In our study as well, mortality was
independent of these variables on multivariate analysis,
Elevated pulmonary capillary wedge pressure during ther-
apy but not at baseline was confirmed to be an independent
predictor of mortality, as described previously
(20),
and the
benefit of caplopril was greatest is patients with a high
pulmonary capillary wedge pressure .
Because late hemodynamic assessment was not per-
formed, it is possible that progressive hemedynamic im-
provement with captopril or deterioration with hydralazine .
or both, occurred . I lowever. previous studies (21 .22) show.
ing a sick of relation between short-term hemodynamic
cllhets of vasodilators and subsequent assessment are not
applicable to this group of patients because they described
patients with less compromised heart failure in whom hemo-
dynamic measurements were obtained after the first asodi-
latordoses, before pharmacokinehc steady state and without
prior nitroprusside and diuretic therapy to establish the
target hemodynamic goals . Long-term maintenance of the
hemodynamic results obtained during tailored therapy was
shown (23) by serial echocardiography in patients similar to
our study group; in those patients the decrease at 24 to 48 h
in estimated pulmonary artery pressures and the reduction in
AV valve regurgitation and atriat volumes were sustained
over lime. Thus . the differential benefit of angiotensin-
converting enzyme inhibition seen in our study most likely
results from a mechanism independent of measurable hemo-
dynamic effects .
Despite an initial mean ejection fraction of 21%, serum
sodium of 136 mgldl, pulmonary capillary wedge pressure of
28 mm 11g and cardiac index of 1 .6 literstmin per tar, the
1-year mortality rate in the patients receiving captopril as
given in this trial was 19%, which is lower than that
previously reported with angiotensin-convening enzyme in-
hibition in advanced heart failure, Although hyponatremic
patients were less likely to have an adequate hemodynamic
response to captopril, in those who did respond . captopril
treatment appeared to reduce mortality . II has been sug-
gested that the benefit of angiotensin-converting enzyme
inhibition may be confined
to these patients who have been
shown to have the most marked activation of me renin-
angiolensin system 118) . In this study. however, a clear
decrease in sudden death occurred with caplopril treatment,
even in patients with normal serum sodium .
Effects of hydralarine. The doses of hydralazine used in
this study of advanced heart failure were on average higher
than those reported for patients with mild to moderate heart
failure and a mean ejection fraction of 3006 (5) . but The
hemodynamic efficacy of these higher doses has previously
been described (15,181
. Hydratazine therapy has been shown
to be associated with progressive activation of the sympa-
thelic nervous system (24) . If such activation occurs when
1
Mirth 15. 19W:W-50
optimal hemodyllatnic status is achieved with direct vasudi-
lation, this may contribute to the survival difference seen
when optimal hemodynamics are instead achieved with
neuronumoral inhibition, as this study was designed to
assess . However, the hydralazine regimen did not itnetf
m to have a negative effect on survival . The I-year
mortality rate of 49% with hydralazine-isosorbide dinitrate
treatment seen in this study is within the range reported for
advanced heart failure treated by empiric dosing of vasodi-
lators that often included angiotensin-convening enzyme
inhibitors 118,25 28) . In the CONSENSUS Trial (6), the
overall mortality rate for the placebo and enalapril groups
combined at I year wns 4746. In a group of patients similar to
those in this study, Lee and Packer (18) reported a I-year
mortality rate of 58%, even though 42%1 of the patients were
receiving angiotensin-converting enzyme inhibitors .
Reduction of sudden death. The mortality reduction with
captopril in this trial was predominantly the result of the
dramatic effect of this agent on sudden death, The sudden
death rate at I-year was 5% in the captopril-treated patients
compared with 37% in the hydralazine-treated patients . This
low rate in the captopril group is lower than expected for
patients with advanced heart failure
referred
for heart trans-
plantation whereas the sudden death rate for hydralazine-
treated patients is similar to that previously reported
(18,25
.30) for such seriously compromised patients. This
sudden death reduction with captopril was not accounted for
by the slightly greater frequency of amiodarone therapy in
captopril-treated patients and type I antiarrhythmic agents in
hydralazine-treated patients because captopril treatment
predicted sudden death-free survival independent of antiar-
rhythmic therapy as assessed by Cox multivariate analysis .
Any bias related to the larger number
of patients with a
history of prior cardiac arrest being treated with captopril
should have favored hydralazine treatment,
In the Veterans Administration Heart Failure Trial 11
U9), the incidence of sudden death was lower with enalapril
than with the hydralazine-isosorbide dinitrate combination
(23% vs. 3706), but this beneficial effect was seen only in
patients with less severe symptoms (functional class I or II) .
The current trial demonstrates that converting enzyme inhi-
bition has a marked impact on sudden death in patients with
advanced heart failure (functional class III or IV). These
results are in contrast to those of the CONSENSUS Trial
(6), in which no reduction in sudden death was discerned
with vasudiiater therapy . The impact
of angiotensin-
converting enzyme inhibition on sudden death in the current
trial may have been exposed because deaths due to progres-
sive heart failure were reduced in both groups, because
patients selected with hemodynamic impairment at rest
underwent therapy tailored to specific thermodynamic goals .
Such therapy has previously been associated with propor-
tionately fewer deaths from progressive heart failure, result-
ing in a greater proportion of deaths occurring suddenly (20).
The progressive heart failure mortality rate in this study was
only 139o overall, whereas 30% of patients in the CONSEN-
tACC
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SUS Trill 161 died of progressive heart failure . It is possible
that captopril may confer additional benefit over that Df
other angiotensin-converting enzyme inhibitors, The greater
impact ofangiotensimconverling enzyme inhibition revealed
in this trial may also reflect the uniform approach to thera-
py-not only for vasodilators. but also for diuretic adjust-
ment and other related management-which can best he
achieved in a single center study
.
Mechanisms. The influence of therapy on sudden death in
heart failure is confounded by the multiple causes of sudden
death in this group of patients 1311 . By altering loading
conditions, reducing wall stress . improving perfusion and
influencing neuroendocrine activation indirectly . any effec-
live vasodilator regimen could theoretically reduce the inci-
dence of complex ventricular tachyarrhythmias and bradyar-
rhythmias that result in sudden death . Specific beneficial
effects of angiotensin-converting enzyme inhibition in addi-
tion to direct hemodynamic improvement may include the
direct antagonism of neuroendocrine activation as well as
antagonism of angiotensin II-mediated progressive ventricu-
lar hypertrophy and dilation shown experimentally (33 .33) .
Other mechanisms include prevention cf aldosterone- and
diuretic-mediated electrolyte deficiency . direct reduction of
myocardial oxygen consumption from inhibition of the local
cardiac resin-angiotensin system 134-361 and restoration of
haroreeeptor sensitivity 1371 . In contrast . direct vasodilation
with hydralazine titrated to hemodynamic goals may result
in progressive neurohumoral activation without alteration of
angiotensin I1-mediated progressive ventricular enlarge-
ment. central autonomic changes and barurellex abnormali-
ties .
Limitations . By virtue of vasodilator dose titration de-
sign, our study was not a double-blind or placebo-controlled
trial . Although the treatment groups had similar baseline
characteristics and hemodynamic status and the treatment
drug was an independent predictor of survival . many pa-
tients . particularly those with hypmatremio, chanced vadu-
dilator regimen. thus raising the possibility that achievement
of hemodynamic goals with captopril merely identifies sur-
vivors
. However, analysis of
the subset of patients who
continued the original vasodilator regimen yielded equiva-
lent differences in mortality, In addition . within the hydrala-
zine treatment group, the mortality and sudden death rates
were identical in patients who continued to receive hydrala-
zinc after randomization and patients who received hydrala-
zine after initial randomization to captopril therapy . This
observation argues that the mortality and sudden death
differences seen in this study do not reflect a cohort of more
compromised patients with unsuccessful captopril therapy
who join the hydralazine treatment group . Daring the initial
hospital stay . b y identifying the vasodilator regimen that
would be tolerated, only 47, of patients were withdrawn
from therapy after discharge . Interpretation of this study
was thus not complicated by later withdrawals for serious
side effects, as occurred in the Veterans Administration
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Heart Failure Trial I (5) ( 43%) and CONSENSUS Trial (6;1
I17cil
.
Because the equivalent majority of patients in each vaso-
dilator group received isnsnrbide dinitrate-the study did nor
result in the compadwn of the combination of hydrutazine
and isos)rbide dinitrate with captoprit alone, but compared
both sasudilaWrs in combination with i ;osorbide dinitrate.
Nitrate therapy itself has been shown to have beneficial
impact 1391. A favorable interaction between captopril and
isusurbide dinitrate . such as the prevention of nitrate toler-
ance . may have contributed to the mortality and sudden
death reduction seen in this study .
This study does not address the optimal design of therapy
for patients who cannot achieve adequate hemodynamic
status without additional direct-acting
vasodilators,
in whom
further investigation will be required to determine the poten-
tial role for combination therapy with both angiotensin-
converting enzyme inhibition and direct vasodilation .
Implications. This study has demonstrated that despite
titration to the same hemodynamic goals. captopril reduced
sudden death and overall mortality in advanced heart failure
compared with hydralazine when both regimens included
isusorbide dinitrate . These results indicate that for patients
with advanced heart failure who can achieve these hemody-
namic goals on a titrated regimen with an angiotensin-
converting enzyme inhibitor . this should be the vasodilator
of choice . even if these goals could have been achieved on a
regimen of direct vasodilation with hydralazinv and isosor-
bide dinitrate
.
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